Table 1 Patient and tumour characteristics by histopathological subtypes
From: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival
| Â | SCC | ASC | AC | P value |
|---|---|---|---|---|
|  | n = 79 | n = 38 | n = 75 |  |
Age (years), mean ± sd | 49.8 ± 14.5 | 43.0 ± 11.7 | 44.7 ± 13.3 | 0.014 |
(95% CI for mean) | (46.6-53.1) | (39.1-46.8) | (41.6-47.7) | Â |
FIGO stage I, n (%) | 64 (81) | 34 (89) | 67 (89) | 0.260 |
FIGO stage II, n (%) | 15 (19) | 4 (11) | 8 (11) | Â |
High-risk HPV positive, n (%) | 75 (95) | 37 (97) | 64 (85) | 0.036 |
- HPV 16 | 51 (68) | 19 (51) | 28 (44) | 0.003 |
- HPV 18 | 13 (17) | 12 (32) | 28 (44) | Â |
- Other | 11 (15) | 6 (16) | 8 (12) | Â |
Tumour size ≥ 40 mm, n (%) | 31 (41) | 16 (42) | 11 (16) | 0.001 |
Infiltration depth ≥ 15 mm, n (%) | 39 (51) | 13 (34) | 17 (24) | 0.003 |
Positive LVSI, n (%) | 47 (60) | 19 (53) | 23 (38) | 0.037 |
Positive resection margins, n (%) | 22 (28) | 4 (11) | 17 (23) | 0.109 |
Positive parametria, n (%) | 8 (10) | 4 (11) | 4 (5) | 0.483 |
Positive lymph nodes, n (%) | 27 (34) | 9 (24) | 15 (20) | 0.125 |
Adjuvant radiotherapy, n (%) | 48 (61) | 18 (47) | 30 (40) | 0.034 |
Follow-up time (months), mean ± sd | 199.4 ± 11.9 | 186.3 ± 16.6 | 201.9 ± 11.0 | 0.782 |
(95% CI for mean) | (176.1-222.6) | (153.9-218.8) | (180.3-223.5) | Â |
Recurrence-free time (months), mean ± sd | 184.2 ± 12.4 | 168.3 ± 17.6 | 148.2 ± 10.5 | 0.977 |
(95% CI for mean) | (160.0-208.4) | (133.8-202.8) | (127.5-168.8) | Â |
Death, all causes, n (%) | 34 (43) | 12 (32) | 22 (29) | 0.177 |
Death by tumour, n (%) | 19 (24) | 10 (26) | 16 (21) | 0.828 |
Recurrent disease, n (%) | 21 (27) | 10 (26) | 19 (24) | 0.984 |